CN113876748A - Atomization method of treprostinil aerosol inhalant for treating pulmonary hypertension - Google Patents
Atomization method of treprostinil aerosol inhalant for treating pulmonary hypertension Download PDFInfo
- Publication number
- CN113876748A CN113876748A CN202111387204.1A CN202111387204A CN113876748A CN 113876748 A CN113876748 A CN 113876748A CN 202111387204 A CN202111387204 A CN 202111387204A CN 113876748 A CN113876748 A CN 113876748A
- Authority
- CN
- China
- Prior art keywords
- treprostinil
- salt
- aerosol
- pulmonary hypertension
- inhaler
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- PAJMKGZZBBTTOY-ZFORQUDYSA-N treprostinil Chemical compound C1=CC=C(OCC(O)=O)C2=C1C[C@@H]1[C@@H](CC[C@@H](O)CCCCC)[C@H](O)C[C@@H]1C2 PAJMKGZZBBTTOY-ZFORQUDYSA-N 0.000 title claims abstract description 88
- 229960005032 treprostinil Drugs 0.000 title claims abstract description 79
- 239000000443 aerosol Substances 0.000 title claims abstract description 64
- 208000002815 pulmonary hypertension Diseases 0.000 title claims abstract description 20
- 238000000889 atomisation Methods 0.000 title claims abstract description 11
- 239000003814 drug Substances 0.000 claims abstract description 55
- 229940079593 drug Drugs 0.000 claims abstract description 30
- 210000004072 lung Anatomy 0.000 claims abstract description 19
- 238000010438 heat treatment Methods 0.000 claims abstract description 18
- 238000000034 method Methods 0.000 claims description 19
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 18
- 150000003839 salts Chemical class 0.000 claims description 13
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims description 9
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 claims description 9
- 239000010419 fine particle Substances 0.000 claims description 9
- 238000005507 spraying Methods 0.000 claims description 9
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims description 8
- 238000000151 deposition Methods 0.000 claims description 8
- 230000000857 drug effect Effects 0.000 claims description 7
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 claims description 6
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 claims description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 5
- 230000008021 deposition Effects 0.000 claims description 5
- 238000001035 drying Methods 0.000 claims description 5
- 238000001704 evaporation Methods 0.000 claims description 5
- IQKAWAUTOKVMLE-ZSESPEEFSA-M treprostinil sodium Chemical class [Na+].C1=CC=C(OCC([O-])=O)C2=C1C[C@@H]1[C@@H](CC[C@@H](O)CCCCC)[C@H](O)C[C@@H]1C2 IQKAWAUTOKVMLE-ZSESPEEFSA-M 0.000 claims description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 5
- BLUGYPPOFIHFJS-UUFHNPECSA-N (2s)-n-[(2s)-1-[[(3r,4s,5s)-3-methoxy-1-[(2s)-2-[(1r,2r)-1-methoxy-2-methyl-3-oxo-3-[[(1s)-2-phenyl-1-(1,3-thiazol-2-yl)ethyl]amino]propyl]pyrrolidin-1-yl]-5-methyl-1-oxoheptan-4-yl]-methylamino]-3-methyl-1-oxobutan-2-yl]-3-methyl-2-(methylamino)butanamid Chemical compound CN[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N(C)[C@@H]([C@@H](C)CC)[C@H](OC)CC(=O)N1CCC[C@H]1[C@H](OC)[C@@H](C)C(=O)N[C@H](C=1SC=CN=1)CC1=CC=CC=C1 BLUGYPPOFIHFJS-UUFHNPECSA-N 0.000 claims description 4
- 208000007934 ACTH-independent macronodular adrenal hyperplasia Diseases 0.000 claims description 4
- 238000002663 nebulization Methods 0.000 claims description 4
- 230000002685 pulmonary effect Effects 0.000 claims description 4
- 239000004381 Choline salt Substances 0.000 claims description 3
- 125000002059 L-arginyl group Chemical class O=C([*])[C@](N([H])[H])([H])C([H])([H])C([H])([H])C([H])([H])N([H])C(=N[H])N([H])[H] 0.000 claims description 3
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical class NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 claims description 3
- MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical class CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 claims description 3
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 claims description 3
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical class OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 claims description 3
- 150000003863 ammonium salts Chemical class 0.000 claims description 3
- 159000000007 calcium salts Chemical class 0.000 claims description 3
- 235000019417 choline salt Nutrition 0.000 claims description 3
- ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical class OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 claims description 3
- WBJINCZRORDGAQ-UHFFFAOYSA-N formic acid ethyl ester Natural products CCOC=O WBJINCZRORDGAQ-UHFFFAOYSA-N 0.000 claims description 3
- 210000003456 pulmonary alveoli Anatomy 0.000 claims description 3
- 150000003248 quinolines Chemical class 0.000 claims description 3
- 230000008016 vaporization Effects 0.000 claims description 3
- 230000008020 evaporation Effects 0.000 claims description 2
- 238000012387 aerosolization Methods 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 6
- 210000001147 pulmonary artery Anatomy 0.000 abstract description 4
- 210000000056 organ Anatomy 0.000 abstract description 3
- 238000012377 drug delivery Methods 0.000 abstract 1
- 239000002245 particle Substances 0.000 description 23
- 239000011888 foil Substances 0.000 description 20
- 241000700159 Rattus Species 0.000 description 8
- 239000000843 powder Substances 0.000 description 8
- 229910052751 metal Inorganic materials 0.000 description 7
- 239000002184 metal Substances 0.000 description 7
- 230000008569 process Effects 0.000 description 7
- 239000000243 solution Substances 0.000 description 7
- RHWRWEUCEXUUAV-ZSESPEEFSA-N 2-[[(1r,2r,3as,9as)-2-hydroxy-1-[(3s)-3-hydroxyoctyl]-2,3,3a,4,9,9a-hexahydro-1h-cyclopenta[g]naphthalen-5-yl]oxy]acetic acid;2-(2-hydroxyethylamino)ethanol Chemical class OCCNCCO.C1=CC=C(OCC(O)=O)C2=C1C[C@@H]1[C@@H](CC[C@@H](O)CCCCC)[C@H](O)C[C@@H]1C2 RHWRWEUCEXUUAV-ZSESPEEFSA-N 0.000 description 6
- 238000009826 distribution Methods 0.000 description 6
- 239000007788 liquid Substances 0.000 description 5
- 239000003826 tablet Substances 0.000 description 5
- 210000001519 tissue Anatomy 0.000 description 5
- 229940014025 tyvaso Drugs 0.000 description 5
- 239000011248 coating agent Substances 0.000 description 4
- 238000000576 coating method Methods 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 238000012512 characterization method Methods 0.000 description 3
- 229940112141 dry powder inhaler Drugs 0.000 description 3
- 230000036470 plasma concentration Effects 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 210000002345 respiratory system Anatomy 0.000 description 3
- 239000007939 sustained release tablet Substances 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 206010067484 Adverse reaction Diseases 0.000 description 2
- 206010011224 Cough Diseases 0.000 description 2
- 208000002193 Pain Diseases 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 230000006838 adverse reaction Effects 0.000 description 2
- 230000002776 aggregation Effects 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 210000004204 blood vessel Anatomy 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 230000007547 defect Effects 0.000 description 2
- 238000004980 dosimetry Methods 0.000 description 2
- 229960001123 epoprostenol Drugs 0.000 description 2
- KAQKFAOMNZTLHT-VVUHWYTRSA-N epoprostenol Chemical compound O1C(=CCCCC(O)=O)C[C@@H]2[C@@H](/C=C/[C@@H](O)CCCCC)[C@H](O)C[C@@H]21 KAQKFAOMNZTLHT-VVUHWYTRSA-N 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 2
- 239000012669 liquid formulation Substances 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 210000000214 mouth Anatomy 0.000 description 2
- 239000008194 pharmaceutical composition Substances 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 229910001220 stainless steel Inorganic materials 0.000 description 2
- 239000010935 stainless steel Substances 0.000 description 2
- 230000009885 systemic effect Effects 0.000 description 2
- 229960001726 treprostinil sodium Drugs 0.000 description 2
- 230000024883 vasodilation Effects 0.000 description 2
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 1
- DPVHGFAJLZWDOC-PVXXTIHASA-N (2r,3s,4s,5r,6r)-2-(hydroxymethyl)-6-[(2r,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxane-3,4,5-triol;dihydrate Chemical compound O.O.O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 DPVHGFAJLZWDOC-PVXXTIHASA-N 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 206010015150 Erythema Diseases 0.000 description 1
- 208000010201 Exanthema Diseases 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 206010021143 Hypoxia Diseases 0.000 description 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- 208000007101 Muscle Cramp Diseases 0.000 description 1
- 206010050661 Platelet aggregation inhibition Diseases 0.000 description 1
- 208000011191 Pulmonary vascular disease Diseases 0.000 description 1
- 206010039163 Right ventricular failure Diseases 0.000 description 1
- 208000034189 Sclerosis Diseases 0.000 description 1
- 208000005392 Spasm Diseases 0.000 description 1
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 1
- 238000005411 Van der Waals force Methods 0.000 description 1
- 208000032594 Vascular Remodeling Diseases 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 238000005054 agglomeration Methods 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 231100000321 erythema Toxicity 0.000 description 1
- 201000005884 exanthem Diseases 0.000 description 1
- 238000003304 gavage Methods 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 125000005842 heteroatom Chemical group 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 208000018875 hypoxemia Diseases 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 229940098453 inhalant powder Drugs 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 238000000691 measurement method Methods 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 239000006199 nebulizer Substances 0.000 description 1
- 229940093719 orenitram Drugs 0.000 description 1
- 230000036285 pathological change Effects 0.000 description 1
- 231100000915 pathological change Toxicity 0.000 description 1
- 230000000079 pharmacotherapeutic effect Effects 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 229940068968 polysorbate 80 Drugs 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 150000003815 prostacyclins Chemical class 0.000 description 1
- 210000002307 prostate Anatomy 0.000 description 1
- 230000036593 pulmonary vascular resistance Effects 0.000 description 1
- 206010037844 rash Diseases 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- 239000012488 sample solution Substances 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 230000035807 sensation Effects 0.000 description 1
- 210000000329 smooth muscle myocyte Anatomy 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 229960000999 sodium citrate dihydrate Drugs 0.000 description 1
- 210000005070 sphincter Anatomy 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 206010042772 syncope Diseases 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 229940126585 therapeutic drug Drugs 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 229940074410 trehalose Drugs 0.000 description 1
- 229940074409 trehalose dihydrate Drugs 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 229940124549 vasodilator Drugs 0.000 description 1
- 239000003071 vasodilator agent Substances 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 238000009423 ventilation Methods 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M11/00—Sprayers or atomisers specially adapted for therapeutic purposes
- A61M11/04—Sprayers or atomisers specially adapted for therapeutic purposes operated by the vapour pressure of the liquid to be sprayed or atomised
- A61M11/041—Sprayers or atomisers specially adapted for therapeutic purposes operated by the vapour pressure of the liquid to be sprayed or atomised using heaters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pulmonology (AREA)
- Epidemiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Otolaryngology (AREA)
- Anesthesiology (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Medicinal Preparation (AREA)
Abstract
The invention discloses an atomization method of treprostinil aerosol inhalant for treating pulmonary hypertension. By utilizing the principle that the medicine forms aerosol at high temperature, treprostinil is coated on a heating sheet of a medicine inhaler, is heated to form gaseous treprostinil which is rapidly condensed to form aerosol, is inhaled into the lung through an air passage, directly acts on a receptor in a pulmonary artery blood vessel, has rapid effect, directly acts on a target spot, has small dosage, is rapidly metabolized and has low dosage distributed to other organs of a human body. The inhalation drug delivery system is convenient for patients to carry and use in daily life, increases the drug compliance of patients, and has good application prospect.
Description
Technical Field
The invention belongs to the field of medicinal preparations, and particularly relates to an atomization method of a treprostinil aerosol inhalant for treating pulmonary hypertension.
Background
Pulmonary hypertension is a malignant pulmonary vascular disease characterized by small pulmonary vascular remodeling, often due to progressive increases in pulmonary vascular resistance and ultimately leading to the death of the right heart failure of the patient. Treprostinil is a targeted therapeutic drug for pulmonary hypertension, belongs to prostacyclin analogues, has similar pharmacological action to endogenous prostacyclin, and has direct vasodilation and platelet aggregation inhibition effects on pulmonary and systemic arterial vascular beds.
The existing preparations developed by treprostinil and marketed by the current market comprise subcutaneous or intravenous injection (Remadulin, 20ml:20mg), sustained release tablets (Orenitram, 0.125mg/0.25mg), inhalant (Tyvaso, 1.74mg/2.9ml) atomized by ultrasonic pulse, the three preparations have long-term pain or reaction at the infusion part, erythema, sclerosis or rash are generated, adverse reactions related to prostacyclin pharmacological characteristics such as blood pressure reduction caused by vasodilation, headache, cough, syncope and aggravation of cheek muscle spasm (oral cavity opening and closing difficulty) can occur in the using process of the sustained release tablets, the daily life of patients is influenced, and the problems of ventilation blood flow ratio imbalance and hypoxemia caused by uneven distribution of medicines exist no matter whether the vein or oral treprostinil treats pulmonary hypertension.
Inhalation administration refers to an administration mode in which one or more drugs enter the deep lung of the respiratory tract via a special administration device to exert local or systemic effects. Inhalation formulations include mainly inhalation aerosols, powder inhalers and liquid formulations for nebulizers 3.
According to the US Patent No. 10076505 "introduction of pharmaceutical formulations of treprostinil", United states treatment company (United Therapeutics Corporation), developed a treprostinil Inhalation system TYVASO, which belongs to a liquid formulation for nebulization, converted the treprostinil liquid pharmaceutical formulation into a nebulized form by the nebulizer and inhaled into the human lung for pharmacotherapeutic effect. According to the US Patent 10898494 "Dry powder inhaler for the treatment of pulmonary hypertension", Liquid Technologies company has invented a treprostinil Dry powder inhaler, belonging to the inhalation powder inhalation, which contains 25 microgram treprostinil in Dry particle dose in a capsule, which is inhaled into the patient by a Dry powder inhaler.
Because pulmonary hypertension belongs to chronic disease, the high period is generally 20 ~ 40 years old, the mild and moderate degree patient who accepts the treatment still can normally go out activity and work, aerosol inhalant Tyvaso is according to the product requirement, need use great, carry inconvenient specific atomizing device, because atomizing equipment adds the liquid medicine after the day need use four times when being awake, use once every four hours, need external power supply during the use, and use or stand-by in-process equipment must not keep flat, empty, need change with the atomized water daily simultaneously, regularly carry out the cleaning and sterilizing operation, therefore the patient uses aerosol inhalant Tyvaso daily very inconveniently, influence its life work quality.
The particle size of the drug particles in the dry powder inhalant and inhalant powder inhalation is small (1-5 μm), the aggregation among the particles is strong due to strong interaction force (van der waals force, electrostatic force and capillary force) among the particles, and the particle size is easy to agglomerate in the storage process to cause particle size change and influence drug effect, so carrier particles are usually needed to hinder the agglomeration phenomenon of the drug powder, carrier particles with the particle size of 70-100 μm are generally added and mixed with drug micropowder with the particle size of 0.5-7 μm, so that the drug micropowder is adsorbed on the surface of the carrier particles, when in use, the drug micropowder and the carrier particles are separated in the inhalation process of a patient, enter the lung of a human body and are deposited, for example, the formula described in the Patent US Patent 10076505 is '1.06% of treprostinil sodium, 92.44% of trehalose dihydrate, 2% of polysorbate 80, 4% of L leucine, 0.27% of sodium citrate dihydrate and 0.23% of sodium chloride', the large-particle-size macromolecular polysaccharide compound trehalose is used as a carrier and is mixed with treprostinil sodium micro powder to prepare the treprostinil inhalant, but in the inhalation and use process of a patient, large-particle auxiliary materials are easily attached to the throat to generate foreign body sensation, the inhalation feeling of the patient is influenced, stress cough is more easily caused to the patient with sensitive throat, the medicine inhaled into the lung is coughed out, and the medicine effect is further reduced.
The patent applicant invented a medicine inhalation device in the earlier stage, with patent application number 202110996422.9, the device comprises a medicine box and a transmitter which are connected with each other, self-administration is carried out at any time through a medicine sending control device, pain is quickly relieved, operation is simple, flexible and convenient, and safety is strong; according to the medicine box, different pieces of foil are sequentially welded on the conductive columns at the two ends of the foil connecting piece, and the conductive columns are electrically connected with the conductive holes, so that different pieces of foil are controlled to be heated, and the medicine feeding is effectively controlled. Based on the device, the invention provides a method for generating treprostinil aerosol inhalant for treating pulmonary hypertension, which is convenient for patients to carry and use daily and increases the medication compliance of the patients.
Disclosure of Invention
In view of the above, the present invention provides an atomization method of treprostinil aerosol inhalant for treating pulmonary hypertension, which utilizes the principle of forming aerosol at high temperature of medicine, coats treprostinil on a heating sheet of a medicine inhalator, the gaseous treprostinil is formed by heating and is quickly condensed to form aerosol, the aerosol is inhaled into the lung through an air passage and directly acts on a receptor in a pulmonary artery blood vessel, compared with Tyvaso aerosol inhalant described in US Patent 10076505, the compound has the same drug effect, overcomes the defect that the patient depends on large-scale atomization equipment in the using process, leads the patient to conveniently carry and use the medicine in daily life, compared with the dry powder inhalant described in the Patent US Patent 10898494, the prescription only contains the components of the raw material medicines, and irritation caused by adhesion of large-particle auxiliary materials to the throat can not be generated in the inhalation process, so that the medication compliance of patients is increased.
The invention mainly solves the technical problems through the following technical scheme.
The inventor finds through experiments that solid treprostinil and its salt can be rapidly gasified to form aerosol with stable quality under the high temperature condition within 500 ℃, and the invention is designed by utilizing the phenomenon that treprostinil molecules contain heteroatoms, can generate strong synergistic effect with polar end groups on the surface of stainless steel, and are adhered to stainless steel foils.
The invention provides an atomization method of treprostinil aerosol inhalant for treating pulmonary hypertension, which comprises the following steps:
step (1), preparing treprostinil or its salt into a solution, uniformly spraying the solution on a heating sheet of a medicine inhaler, and drying;
step (2), the patient inhales air, and the medicine inhaler is started to heat;
and (3) rapidly raising the temperature to 100-500 ℃, rapidly evaporating and vaporizing treprostinil, contacting with the passing air flow to form aerosol, entering the lung of the patient along with the air flow, and depositing on the alveolus to play a drug effect.
Preferably, in the step (1), the treprostinil salt is selected from one of treprostinil sodium salt, calcium salt, diethanolamine salt, triethanolamine salt, L-arginine salt, lysine salt, meglumine salt, ammonium salt and choline salt.
Preferably, in the step (1), the dosage of the treprostinil or the salt thereof is 1.2-1000 [ mu ] g/cm in terms of treprostinil and the spraying amount is 1.2-1000 [ mu ] g/cm2。
Preferably, in the step (1), treprostinil or its salt is dissolved in one or more of a mixture of acetone, methanol, absolute ethanol, ethyl acetate, ethyl formate, isopropanol, n-butanol, triethylamine and water for spray coating.
Preferably, in the step (2), when the inhaled air flow of the patient is 15-60L/min, the flow rate of the air flow passing through the heating sheet is adjusted to be 0.2-20L/min.
Preferably, in step (2), the heating is initiated by applying a current pulse of 0.1 to 2 seconds, a voltage intensity of 0.1 to 10 volts to a heater chip of the medicament inhaler.
Preferably, in step (3), after evaporation by heating, the single-dose delivered is 2 μ g to 90 μ g in terms of treprostinil.
Preferably, in step (3), the delivered treprostinil aerodynamic diameter MMAD is between 0.5 and 5 μm and the fine particle effective deposition rate FPF is between 60% and 99%.
Compared with the prior art, the invention has the positive improvement effects that:
the treprostinil aerosol inhalant can directly act on a pathological change part of a respiratory system without absorption after administration, is combined with a receptor in a pulmonary artery blood vessel to play a role, has quick response, has small dosage and rapid metabolism because of directly acting on a target point, has low dosage distributed to other organs of a human body, and has obvious adverse reaction advantages compared with an injection and a sustained-release tablet.
Compared with the dry powder inhalant, the inhalant has the same drug effect, overcomes the defect that the inhalant depends on large-scale atomization equipment in the using process, and is convenient for patients to carry and use in daily life.
Detailed Description
A method of aerosolizing a treprostinil aerosol inhaler for treatment of pulmonary hypertension, comprising the steps of:
step (1), preparing treprostinil or its salt into a solution, uniformly spraying the solution on a heating sheet of a medicine inhaler, and drying;
step (2), the patient inhales air, and the medicine inhaler is started to heat;
and (3) rapidly raising the temperature to 100-500 ℃, rapidly evaporating and vaporizing treprostinil, contacting with the passing air flow to form aerosol, entering the lung of the patient along with the air flow, and depositing on the alveolus to play a drug effect.
The treprostinil aerosol inhalant is a selective pulmonary vasodilator, because resistance blood vessels before capillaries are surrounded by alveoli, the adjacent anatomical characteristics of the alveoli-capillaries determine that the medicine can generate action by an inhalation mode, the local concentration of the alveoli is higher after the inhalation, and the medicine directly acts on sphincter muscles and smooth muscle cells of the resistance blood vessels before the capillaries by diffusion, so that the treprostinil aerosol inhalant has incomparable targeted therapeutic action in other ways. The invention utilizes the principle that the medicine forms aerosol at high temperature, coats treprostinil on a metal foil, forms gaseous treprostinil by heating and quickly coagulates to form aerosol, and the aerosol is inhaled into the lung through an air passage and directly acts on a receptor in a pulmonary artery blood vessel.
In the present invention, the apparatus for generating treprostinil aerosol inhalation is based on the medicinal inhalation apparatus disclosed in patent 202110996422.9, and it is preferable that treprostinil or its salt is prepared as a solutionUniformly sprayed on the metal foil array of the drug inhaler and dried. The solution of the prostate denier or the salt thereof is prepared by dissolving treprostinil or the salt thereof in one or more of acetone, methanol, absolute ethyl alcohol, ethyl acetate, ethyl formate, isopropanol, n-butanol, triethylamine and water for spraying, and preferably one or more of acetone, methanol, absolute ethyl alcohol and water. Wherein the treprostinil salt is selected from one of treprostinil sodium salt, calcium salt, diethanolamine salt, triethanolamine salt, L-arginine salt, lysine salt, meglumine salt, ammonium salt and choline salt; the present invention preferably sprays treprostinil or treprostinil diethanolamine salt onto a metal foil array of a medicament inhaler; the dosage of the treprostinil or the salt thereof coated on the foil is calculated by the treprostinil, and the spraying amount is 1.2-1000 mu g/cm2The preferred spraying amount is 20-380 mu g/cm2More preferably 100 to 200. mu.g/cm2. In the present invention, the source of treprostinil or its salt is not particularly limited, and a commercially available product may be used.
In the present invention, the heating of the drug inhaler is generated by a current pulse having a duration of 0.2 to 0.6 seconds and a voltage intensity of 0.1 to 10 volts, so that the metal foil is rapidly heated to 100 to 500 ℃, preferably the metal foil is heated to 250 to 350 ℃, more preferably 300 ℃. The inventor finds through experiments that the solid treprostinil and the salt thereof can be rapidly gasified to form aerosol with stable quality under the high-temperature condition within 500 ℃.
In the invention, when the inhaled airflow of a patient is 15-60L/min, airflow shunt control is used, the flow rate of the airflow passing through the metal foil is adjusted to be 0.2-20L/min, so that treprostinil aerosol enters the body along with the airflow, and tests show that stable aerosol particle size distribution can be obtained when the airflow speed passing through the heating plate is in the range. Preferably, the flow rate of the gas flow passing through the metal foil is adjusted to be 1L/min-8L/min, more preferably 5L/min; the drug effect can be achieved by the once delivered dose of 2 mu g to 90 mu g calculated by treprostinil, preferably 5 mu g to 50 mu g, more preferably 10 mu g to 30 mu g, and most preferably 20 mu g.
In the present invention, the delivered treprostinil aerodynamic diameter MMAD is between 0.5-5 μm, the particle size distribution of the drug powder is a key factor affecting the inhalation efficiency of the inhalant, particles larger than this range are mostly deposited in the upper respiratory tract, and particles smaller than this range are easily exhaled or adhered to the oral cavity. The effective deposition rate FPF of the fine particles is 60-99%, the effective deposition rate FPF of the fine particles is calculated by measuring the ratio of the content of the fine particles with the particle size of 0-5.0 mu m to the content of the main drug in each dose, and the particles with the particle size of 0.5-5 mu m can be deposited in the lung, so that the larger the index is, the more the proportion of the drug deposited in the lung is reflected. The preferred delivery treprostinil aerodynamic diameter MMAD is between 1-3 μm and the fine particle effective deposition rate FPF is between 90% -99%.
The present invention will be described in detail with reference to examples for better understanding the objects, technical solutions and advantages of the present invention, but they should not be construed as limiting the scope of the present invention. The experimental procedures, in which specific conditions are not noted in the following examples, are generally carried out under conventional conditions or conditions recommended by the manufacturers.
Example 1
120mg of treprostinil is precisely weighed into a volumetric flask, 10ml of methanol is added, and the mixture is shaken to be dissolved. Applying the medicinal liquid to foil array of medicinal inhaler with high precision ultrasonic atomization coating machine at a coating amount of 30 μ g/cm2And (5) drying. In use, a patient inhales air, a heating controller in the inhalation system applies a pulse current of 3 volts for 0.3 second to the foil to rapidly heat the foil to 300 ℃ and vaporize treprostinil to form aerosol, and an airflow distribution controller in the inhaler controls the airflow passing over the foil to be 2-7L/min to bring about 6 μ g of treprostinil aerosol into the human body.
Example 2
Precisely weighing 300mg of treprostinil diethanolamine salt, placing into a volumetric flask, adding 10ml of absolute ethanol, and shaking to dissolve. Applying the medicinal liquid to foil array of medicinal inhaler with high-precision ultrasonic atomization coating machine at a coating amount of 90 μ g/cm2And (5) drying. In use, the patient inhales air, heating in the inhalation systemThe controller will pulse the foil with a current of 4.5 volts for 0.5 seconds to rapidly heat the foil to 250 c and vaporize the treprostinil diethanolamine salt to form an aerosol, and the air flow split controller in the inhaler controls the air flow through the foil at 2-7L/min to bring about 15 μ g of treprostinil diethanolamine salt aerosol into the body.
Example 3 delivery dosimetry
The delivered dose of treprostinil aerosol prepared in example 1 and treprostinil diethanolamine aerosol prepared in example 2 were measured using DUSA tube (unit dose sampling device) method according to the requirement of uniformity of delivered dose in chinese pharmacopoeia.
The DUSA pipe is connected to the air suction port of the aerosol system, the vacuum pump is started, and the flow meter throttle valve is adjusted to enable the flow to reach 28.3L/min (+ -5%). The aerosol system was connected to a DUSA tube equipped with a filter membrane using a suitable rubber port to ensure the seal of the junction, the sample was sprayed once into the DUSA tube, methanol and sodium hydroxide solution were added using a pipette, vortexed for 30s, sonicated for 10min, the supernatant was taken as the test sample solution, the operation was repeated 10 times, the measurement was performed using high performance liquid chromatography, and the average delivered dose and standard deviation were calculated, the results are shown in table 1.
TABLE 1 treprostinil Aerosol System delivered dosimetry
Example 4 determination of the aerodynamic properties of aerosol fine particles.
According to 0951 fine particle aerodynamic characteristics measurement method of inhalation formulation in the four parts of Chinese pharmacopoeia, particle size characterization is performed on treprostinil aerosol prepared in example 1 and treprostinil diethanolamine aerosol prepared in example 2, aerosol emission is performed by using a heating controller in an inhalation system, aerosol is collected by using an NGI (next generation impact) device under the conditions that the inhalation airflow is 30L/min +/-1.5L/min, the air temperature is 25 +/-5 ℃, and the relative humidity is 50.0 +/-5%, 10 times of emitted aerosol is collected in each test, and aerodynamic droplet size distribution is evaluated.
The following table summarizes the results of the aerosol characterization experiment described above (n ═ 5):
TABLE 2 Treprostinil Aerosol System Fine particle aerodynamic characterization
Example 5
Treprostinil aerosol inhalation administration compared to oral administration, plasma concentrations in rats and distribution in rat lung tissue
Taking 12 SD rats (200g +/-20 g), 6 treprostinil tablets in an intragastric group, and administering the dose of 600 mu g/rat; treprostinil aerosol inhalant (example 1) group: 6 drugs were delivered directly to the lungs of anesthetized, ventilated rats at a dose of 1.2. mu.g/mouse. Plasma treprostinil drug concentrations were determined using LC-MS at 10min, 30min, 1h, 2h, 4h, and 6h, respectively, and the area under the drug time curve AUC0-6h, maximum plasma concentration Cmax, and plasma peak arrival time Tmax from 0 to 6 hours were calculated from the drug concentrations, and the results are shown in Table 3.
Another 48 SD rats (200g +/-20 g) and 24 treprostinil tablets are taken, and the administration dose is 600 mu g/mouse; treprostinil aerosol inhalation group: 24 were administered at a dose of 1.2. mu.g/mouse. 4 rats were dissected per group at 10min, 30min, 1h, 2h, 4h, and 6h, respectively, lung tissue drug concentration was determined using LC-MS, and the area under the curve AUC0-6h, maximum blood drug concentration Cmax, and blood peak time Tmax at 0 to 6 hours drug time were calculated from the drug concentration, and the results are shown in Table 3.
TABLE 3 treprostinil Aerosol comparison of plasma levels in whole blood and lungs with oral administration in rats by inhalation
As shown in Table 3, the results of the drug concentration in the plasma show that the drug concentration of the aerosol inhalant in the whole body plasma is significantly lower than that of the tablet intragastric administration group, and the drug peak time is faster than that of the tablet intragastric administration group, which indicates that the aerosol inhalant has low influence on other organs of the whole body after entering the body. Meanwhile, as shown in the results of the drug concentration in the lung tissue shown in table 3, the drug concentration of the aerosol inhalant in the lung tissue is slightly higher than that of the tablet, but the Cmax can reach more than 2 times of the Cmax of the gavage group, which indicates that the treprostinil aerosol inhalant can quickly reach higher concentration in the lung tissue to take effect after being inhaled.
The above description is only a preferred embodiment of the present invention and is not intended to limit the present invention, and various modifications and changes may be made by those skilled in the art. Any modification, equivalent replacement, or improvement made within the spirit and principle of the present invention should be included in the protection scope of the present invention.
Claims (8)
1. A method of aerosolizing a treprostinil aerosol inhaler for treatment of pulmonary hypertension, comprising the steps of:
step (1), preparing treprostinil or its salt into a solution, uniformly spraying the solution on a heating sheet of a medicine inhaler, and drying;
step (2), the patient inhales air, and the medicine inhaler is started to heat;
and (3) rapidly raising the temperature to 100-500 ℃, rapidly evaporating and vaporizing treprostinil, contacting with the passing air flow to form aerosol, entering the lung of the patient along with the air flow, and depositing on the alveolus to play a drug effect.
2. The nebulization method of treprostinil aerosol inhaler for treatment of pulmonary hypertension according to claim 1, characterized in that in step (1) the treprostinil salt is selected from one of treprostinil sodium salt, calcium salt, diethanolamine salt, triethanolamine salt, L-arginine salt, lysine salt, meglumine salt, ammonium salt, choline salt.
3. The method of claim 1 for treating pulmonary hypertensionThe atomization method of the treprostinil aerosol inhalant is characterized in that in the step (1), the dosage of the treprostinil or the treprostinil salt is calculated by the treprostinil, and the spraying amount is 1.2-1000 mu g/cm2。
4. The nebulization method of treprostinil aerosol inhaler for treatment of pulmonary hypertension according to claim 1, characterized in that in step (1), treprostinil or its salt is sprayed in one or more of acetone, methanol, absolute ethanol, ethyl acetate, ethyl formate, isopropanol, n-butanol, triethylamine and water.
5. The aerosolization method for a treprostinil aerosol inhaler for treating pulmonary hypertension according to claim 1, wherein in step (2), the flow rate of the air flow through the heating plate is adjusted to be 0.2L/min to 20L/min when the patient inhales at an amount of 15-60L/min.
6. A method of nebulizing treprostinil aerosol inhaler for treatment of pulmonary hypertension according to claim 1 characterized in that in step (2) the heating is activated by a current pulse of 0.1 to 2 seconds, a voltage intensity of 0.1 to 10 volts, administered to a heating plate of a drug inhaler.
7. A method of nebulizing a treprostinil aerosol inhaler for treatment of pulmonary hypertension according to claim 1, characterized in that in step (3) after heat evaporation, the delivered dose in one time is 2 μ g to 90 μ g in treprostinil.
8. A method of nebulization of a treprostinil aerosol inhaler for treatment of pulmonary hypertension according to claim 1 characterized in that in step (3) the delivered treprostinil aerodynamic diameter MMAD is between 0.5-5 μm and the fine particle effective deposition rate FPF is between 60% -99%.
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202111387204.1A CN113876748A (en) | 2021-11-22 | 2021-11-22 | Atomization method of treprostinil aerosol inhalant for treating pulmonary hypertension |
| PCT/CN2021/132791 WO2023087345A1 (en) | 2021-11-22 | 2021-11-24 | Atomization method for treprostinil aerosol inhalant for treatment of pulmonary hypertension |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202111387204.1A CN113876748A (en) | 2021-11-22 | 2021-11-22 | Atomization method of treprostinil aerosol inhalant for treating pulmonary hypertension |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN113876748A true CN113876748A (en) | 2022-01-04 |
Family
ID=79015428
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202111387204.1A Pending CN113876748A (en) | 2021-11-22 | 2021-11-22 | Atomization method of treprostinil aerosol inhalant for treating pulmonary hypertension |
Country Status (2)
| Country | Link |
|---|---|
| CN (1) | CN113876748A (en) |
| WO (1) | WO2023087345A1 (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114732789A (en) * | 2022-05-05 | 2022-07-12 | 中国药科大学 | Compound long-acting drug delivery system for treating pulmonary hypertension and preparation thereof |
| WO2023206444A1 (en) * | 2022-04-29 | 2023-11-02 | 兆科药业（广州）有限公司 | Treprostinil soft mist inhalant |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101495122A (en) * | 2006-05-15 | 2009-07-29 | 联合治疗公司 | Treprostinil administration using a metered dose inhaler |
| CN101596175A (en) * | 2001-06-05 | 2009-12-09 | 艾利斯达医药品公司 | Be used to suck the aerocolloidal formation method of sending |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20070122353A1 (en) * | 2001-05-24 | 2007-05-31 | Hale Ron L | Drug condensation aerosols and kits |
| US7090830B2 (en) * | 2001-05-24 | 2006-08-15 | Alexza Pharmaceuticals, Inc. | Drug condensation aerosols and kits |
| US7766013B2 (en) * | 2001-06-05 | 2010-08-03 | Alexza Pharmaceuticals, Inc. | Aerosol generating method and device |
| US7550133B2 (en) * | 2002-11-26 | 2009-06-23 | Alexza Pharmaceuticals, Inc. | Respiratory drug condensation aerosols and methods of making and using them |
| DK3268072T3 (en) * | 2015-03-11 | 2024-01-22 | Alexza Pharmaceuticals Inc | USE OF ANTISTATIC MATERIALS IN THE AIRWAY FOR THERMAL AEROSOL CONDENSATION PROCESS |
| WO2019152873A1 (en) * | 2018-02-02 | 2019-08-08 | Alexza Pharmaceuticals, Inc. | Electrical condensation aerosol device |
-
2021
- 2021-11-22 CN CN202111387204.1A patent/CN113876748A/en active Pending
- 2021-11-24 WO PCT/CN2021/132791 patent/WO2023087345A1/en unknown
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101596175A (en) * | 2001-06-05 | 2009-12-09 | 艾利斯达医药品公司 | Be used to suck the aerocolloidal formation method of sending |
| CN101495122A (en) * | 2006-05-15 | 2009-07-29 | 联合治疗公司 | Treprostinil administration using a metered dose inhaler |
Non-Patent Citations (1)
| Title |
|---|
| 吴超君等: "曲前列尼尔治疗肺动脉高压给药途径和不良反应的护理进展", 《护理研究》 * |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2023206444A1 (en) * | 2022-04-29 | 2023-11-02 | 兆科药业（广州）有限公司 | Treprostinil soft mist inhalant |
| CN114732789A (en) * | 2022-05-05 | 2022-07-12 | 中国药科大学 | Compound long-acting drug delivery system for treating pulmonary hypertension and preparation thereof |
| CN114732789B (en) * | 2022-05-05 | 2023-08-22 | 中国药科大学 | Compound long-acting drug delivery system for treating pulmonary hypertension and preparation thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| WO2023087345A1 (en) | 2023-05-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Newman | Aerosol deposition considerations in inhalation therapy | |
| Ari et al. | Inhalation therapy in patients receiving mechanical ventilation: an update | |
| Harb et al. | Performance of large spacer versus nebulizer T-piece in single-limb noninvasive ventilation | |
| JP2021102620A (en) | Dry powder formulations and methods of use | |
| EA003405B1 (en) | Method and device for delivering an aerosolized active agent to the lungs of a human patient | |
| US20190046436A1 (en) | Nicotine formulation and aerosols | |
| CN113876748A (en) | Atomization method of treprostinil aerosol inhalant for treating pulmonary hypertension | |
| KR20040097351A (en) | Therapeutic dry powder preparation | |
| JP2001513492A (en) | Aqueous aerosol formulation containing bioactive macromolecules and method for producing the aerosol | |
| JP2006527046A (en) | Powder aerosol feeder | |
| WO2008134668A2 (en) | Heat-labile prodrugs | |
| Byron | Some future perspectives for unit dose inhalation aerosols | |
| KR20110091505A (en) | Method for treatment of copd and other pulmonary diseases | |
| CN103619323B (en) | Administration as the iloprost of aerosol group | |
| Ariyananda et al. | Aerosol delivery systems for bronchial asthma | |
| SK10942001A3 (en) | Compressed air inhaler for pulmonary application of liposomal powder aerosols and powder aerosols suitable therefor | |
| KR20210019604A (en) | Use of antistatic materials in the airway for thermal aerosol condensation process | |
| JP2022137070A (en) | Dry powder compositions containing magnesium stearate | |
| Calvert et al. | Enhanced delivery of nebulised salbutamol during non‐invasive ventilation | |
| Fink et al. | Aerosol therapy in mechanically ventilated patients: recent advances and new techniques | |
| CN114652704A (en) | Tryprostinil soft mist inhalant | |
| WO2015014209A1 (en) | Pyruvate pharmaceutical compositions for osmotic stability and detoxification effect thereof in healthy human beings and lung disease patients | |
| CN110680811A (en) | Ambroxol dry powder for inhalation using bronchus as target | |
| EP0166476B1 (en) | Aerosol generator-inhalator | |
| US6462090B1 (en) | Formulations for detecting asthma |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20220104 |
|
| RJ01 | Rejection of invention patent application after publication |